Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PKCδ-targeted intervention relieves chronic pain in a murine sickle cell disease model
Ying He, … , Robert E. Molokie, Zaijie Jim Wang
Ying He, … , Robert E. Molokie, Zaijie Jim Wang
Published June 27, 2016
Citation Information: J Clin Invest. 2016;126(8):3053-3057. https://doi.org/10.1172/JCI86165.
View: Text | PDF
Brief Report Hematology

PKCδ-targeted intervention relieves chronic pain in a murine sickle cell disease model

  • Text
  • PDF
Abstract

Pain is a life-long symptom in sickle cell disease (SCD) and a predictor of disease progression and mortality, but little is known about its molecular mechanisms. Here, we characterized pain in a targeted knockin mouse model of SCD (TOW mouse) that exclusively expresses human alleles encoding normal α- and sickle β-globin. TOW mice exhibited ongoing spontaneous pain behavior and increased sensitivity to evoked pain compared with littermate control mice expressing normal human hemoglobins. PKCδ activation was elevated in the superficial laminae of the spinal cord dorsal horn in TOW mice, specifically in GABAergic inhibitory neurons. Functional inhibition and neuron-specific silencing of PKCδ attenuated spontaneous pain, mechanical allodynia, and heat hyperalgesia in TOW mice. Furthermore, we took a hematopoietic stem cell transplantation approach to generating a SCD model in PKCδ-deficient mice. Neither spontaneous pain nor evoked pain was detected in the mice lacking PKCδ despite full establishment of SCD phenotypes. These findings support a critical role of spinal PKCδ in the development of chronic pain in SCD, which may become a potential target for pharmacological interventions.

Authors

Ying He, Diana J. Wilkie, Jonathan Nazari, Rui Wang, Robert O. Messing, Joseph DeSimone, Robert E. Molokie, Zaijie Jim Wang

×

Figure 3

Sickle cell pain behaviors in mice after neuronal PKCδ silencing and in PKCδ-KO mice.

Options: View larger image (or click on image) Download as PowerPoint
Sickle cell pain behaviors in mice after neuronal PKCδ silencing and in ...
(A) Spinal delivery of RVG-9R/PKCδ-siRNA (2 μg/d for 3 days, i.t.) specifically knocked down PKCδ (red) in NeuN-positive (green) cells. Scale bars: 20 μm. n = 15 slices from 3 mice. PKCδ fluorescent intensity across representative cells (indicated by dashed arrows) is illustrated in the chart. Mechanical (B) and thermal (C) sensitivities were tested before and after siRNA treatments. Arrows denote siRNA injections. *P < 0.05, **P < 0.01, ***P < 0.001 vs. hβS/hβS-scr; #P < 0.05, ###P < 0.001 vs. hβA/hβA-siRNA. n = 8/group. (D) When tested on day 4, lidocaine produced CPP in TOW mice treated with RVG-9R/scrambled (scr) RNA duplex, not RVG-9R/PKCδ-siRNA. ***P < 0.001. n = 6/group. (E) Mechanical allodynia and (F) thermal hyperalgesia developed in PKCδ-WT mice, not PKCδ-KO mice, after hematopoietic stem cell transplant from donor TOW mice. ***P < 0.001 vs. pre. n = 6/group. (G) Lidocaine produced CPP paradigm in PKCδ-WT mice, not PKCδ-KO mice, 4 weeks after transplant. ***P < 0.001. n = 6/group. Data were analyzed by ANOVA followed by Dunnett’s t test. Two-way ANOVA (pairing vs. treatment) and post hoc Bonferroni’s test were used to analyze CPP data

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts